TWD
ESPR

True Wealth Design’s Esperion Therapeutics ESPR Stock Holding History

True Wealth Design’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$4 – 2748
2025
Q4 		$4 Buy
+1
New +$3 ﹤0.01% 2549
2025
Q2 		– Sell
-22
Closed -$32 – 2657
2025
Q1 		$32 Buy
+22
New +$41 ﹤0.01% 2494

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

True Wealth Design's ESPR Position: Q1 2026 in Review

True Wealth Design sold out of Esperion Therapeutics (ESPR) in Q1 2026, closing a stake of 1 share — an estimated $4 sold.

True Wealth Design first reported a position in ESPR in Q1 2025 and held it in 2 quarters. The position peaked at $32 in Q1 2025. 207 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

  • True Wealth Design reported no remaining Esperion Therapeutics position as of Q1 2026 after selling out during the quarter.
  • True Wealth Design sold 1 Esperion Therapeutics share in Q1 2026, an estimated $4.
  • True Wealth Design first reported a position in Esperion Therapeutics in Q1 2025 and held it in 2 quarters.
  • True Wealth Design's Esperion Therapeutics position peaked at $32 in Q1 2025.
  • 207 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on True Wealth Design's 13F filing for Q1 2026, filed 13 Apr 2026.